Literature DB >> 20128565

Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema.

Weiye Li1, Stephen H Sinclair, Guo-Tong Xu.   

Abstract

BACKGROUND AND
OBJECTIVE: To determine the effects of intravitreal injections of erythropoietin in eyes with severe, chronic diabetic macular edema, 5 eyes of 5 patients underwent injections of rHuEPO alpha (EPO). PATIENTS AND METHODS: All eyes had progressive vision loss and persistent or worsening edema with prior multi-modal treatment. EPO (5U/50 microL) was injected intravitreally every 6 weeks for three doses and followed for an additional 6 weeks with complete ocular examinations, fluorescein angiography, optical coherence tomography (OCT), and central field acuity perimetry.
RESULTS: Visual acuity of all patients was subjectively improved by 3 or more lines in 3 eyes and 1 line in 2 eyes. Visual acuity improved to a larger extent than anatomic improvement by OCT. Clearing of hard exudates but only minor improvement in leakage on fluorescein angiography was observed. Improvement in vision occurred within 1 week after the first injection and was maintained until the end point of the current case series (at 18 weeks after the first injection).
CONCLUSION: This case series seems to show a short-term positive response to EPO for a specific group of patients with chronic diabetic macular edema who were unresponsive to currently available therapies. Copyright 2010, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128565     DOI: 10.3928/15428877-20091230-03

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  23 in total

Review 1.  Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy.

Authors:  Sayon Roy; Timothy S Kern; Brian Song; Caren Stuebe
Journal:  Am J Pathol       Date:  2016-11-12       Impact factor: 4.307

2.  Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells.

Authors:  Jin Ku Kang; Chang-Hyun Chang; Hyo Jung Nam; Sung-Kuk Kim; Keun Jae Ahn; Heon Seok; Sang Joon Park; Yoon Joong Kang; Young Suk Jo; Minho Shong; Ho Kim
Journal:  Cell Oncol (Dordr)       Date:  2011-01-18       Impact factor: 6.730

3.  Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial.

Authors:  Morteza Entezari; Zahra Kiani Flavarjani; Alireza Ramezani; Humayon Nikkhah; Saeed Karimi; Hamid Fateh Moghadam; Narsis Daftarian; Mehdi Yaseri
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-10       Impact factor: 3.117

4.  Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human.

Authors:  Ugur Acar; Bekir Kucuk; Mehmet Koray Sevinc; Seckin Aykas; Mesut Erdurmus; Gungor Sobaci
Journal:  Int Ophthalmol       Date:  2017-05-19       Impact factor: 2.031

5.  Toxicity of endogenous peroxynitrite and effects of puerarin on transplanted retinal pigment epithelial sheets in the subretinal space in mice.

Authors:  Li-Na Hao; Yan-Qing Zhang; Yu-Hua Shen; Mei-Qiao Li; Tao Yang; Zhi-Hua Zhao; Zhi-Yun Wang; Yan-Hua Wang; Shou-Zhi He
Journal:  Int J Ophthalmol       Date:  2011-06-18       Impact factor: 1.779

Review 6.  Novel targets against retinal angiogenesis in diabetic retinopathy.

Authors:  Shuang Wang; James K Park; Elia J Duh
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

7.  Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment.

Authors:  Z Xie; F Chen; X Wu; C Zhuang; J Zhu; J Wang; H Ji; Y Wang; X Hua
Journal:  Eye (Lond)       Date:  2011-10-21       Impact factor: 3.775

8.  Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy.

Authors:  Carmel M McVicar; Liza M Colhoun; Jodie L Abrahams; Claire L Kitson; Ross Hamilton; Reinhold J Medina; Dash Durga; Tom A Gardiner; Pauline M Rudd; Alan W Stitt
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

9.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31

Review 10.  Revisiting the role of erythropoietin for treatment of ocular disorders.

Authors:  S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.